D2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder.

Abstract

UNLABELLED OBJECTIVE/INTRODUCTION: Lurasidone is an atypical antipsychotic medication approved for the treatment of schizophrenia over a dose range of 40-160 mg/day. This study examined D2 receptor occupancy and its association with clinical improvement and side effects in patients with schizophrenia or schizoaffective disorder following repeated doses of… (More)
DOI: 10.1017/S109285291300059X

Topics

4 Figures and Tables

Slides referencing similar topics